SciELO - Scientific Electronic Library Online

 
vol.45 número3Niveles séricos de 25-hidroxivitamina D y su relación con síndrome metabólico en una población de hombres jóvenes no diabéticosRevisión bibliométrica de COVID-19 en el periodo diciembre 2019 y julio 2020 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Acta Medica Colombiana

versión impresa ISSN 0120-2448

Resumen

BERNAL,, Édgar et al. Hydroxychloroquine for treatment of SARS-CoV-2 infection An exploratory review. Acta Med Colomb [online]. 2020, vol.45, n.3, pp.28-40.  Epub 06-Jun-2021. ISSN 0120-2448.  https://doi.org/10.36104/amc.2020.1880.

Introduction:

hydroxychloroquine has been recommended in this pandemic as a possible effective treatment for COVID-19. This is because Chinese experts have demonstrated its ability to inhibit viral replication through various mechanisms. At this juncture, it is vitally important to understand the latest research and clinical trials regarding an effective treatment regimen which would help improve the treatment of patients with SARS-CoV-2 infection.

Objective:

to present the available information regarding the use of hydroxychloroquine as a treatment option for patients infected with SARS-CoV-2.

Material and methods:

a review was carried out following the methodological framework proposed by Arksey and O'Malley. The data bases used were: PubMed, MedLine, Lilacs, Scopus, Clinical Trials, Cochrane and CNKI. Only texts in Spanish and English were included. Finally, the pertinent studies for this review were described and summarized.

Results:

a total of 87 academic articles were included in the review, including experimental and non-experimental studies, all containing evidence regarding the use of hydroxychloroquine in COVID-19.

Conclusions:

To date, there is no available substantiating scientific data with enough evidence to support the use of hydroxychloroquine as a pharmacological treatment for the current pandemic. Two randomized clinical trials contradict each other regarding the efficacy of hydroxychloroquine. However, they both share methodological errors and have small sample sizes. A single nonrandomized trial with the same errors shows efficacy of hydroxychloroquine. As far as the safety profile, there is data showing a lower rate of adverse effects for hydroxychloroquine compared with chloroquine, so its use would be preferred if it were to be proven effective against COVID-19. There are several randomized clinical trials underway which, it is hoped, will answer the questions raised by the literature review.(Acta Med Colomb 2020; 45. DOI:https://doi.org/10.36104/amc.2020.1880).

Palabras clave : treatment; COVID-19; coronavirus; SARS-CoV-2.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )